DHR · News · 20261106N
Regulatory Approval Milestones
DANAHER CORP /DE/ · 2026-11-06 · Importance 31 · Surprise 42 · In source text
The FDA cleared Cepheid’s Xpert Hemorrhagic Fever Panel and Beckman Coulter’s Access MeMed BV assay. The clearances add products to Danaher’s infectious disease and antimicrobial testing portfolio. The report does not provide sales, adoption, or market-size data for either assay.
Key facts
- Danaher received FDA clearance for its Cepheid Xpert Hemorrhagic Fever Panel. source
- Danaher received FDA clearance for its Beckman Coulter Access MeMed BV assay. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | contingent | — | Danaher received FDA clearance for its Cepheid Xpert Hemorrhagic Fever Panel. |
| revenue | positive | contingent | — | Danaher received FDA clearance for its Beckman Coulter Access MeMed BV assay. |